5.86MMarket Cap-123P/E (TTM)
1.3100High1.2700Low96.72KVolume1.3000Open1.3000Pre Close126.20KTurnover2.22%Turnover RatioLossP/E (Static)4.48MShares15.060052wk High-4.83P/B5.70MFloat Cap1.250052wk Low--Dividend TTM4.35MShs Float5032.5000Historical High--Div YieldTTM3.08%Amplitude1.2500Historical Low1.3040Avg Price1Lot Size
Alzamend Neuro Stock Forum
Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'
Benzinga· just
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023.
Identified by an independent safety review committee, this MTD represents a pivotal ...
Larger Image: tradingview.com...
$Alzamend Neuro (ALZN.US)$
No comment yet